Last reviewed · How we verify

NCT03368703

Physiopathology of Lower Cortical Activation in COPD Patients: Contribution of Cortical Neuromodulation

Completed NA Last updated 13 January 2020
What this trial tests

NA trial testing Anodal transcranial direct-current-stimulation in Physiology in 34 participants. Completed in 30 June 2018.

Timeline
1 June 2017
Primary endpoint
30 June 2018
30 June 2018

Quick facts

Lead sponsor5 Santé
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment34
Start date1 June 2017
Primary completion30 June 2018
Estimated completion30 June 2018
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

5 Santé

Who can join

Adults 45 to 75, any sex, with Physiology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with COPD have lower cortical activation and higher cortical inhibitory levels. The purpose of this study is to test the reversibility the lower cortical activation by counterbalancing the increased cortical inhibitory levels with neuro-modulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Physiology

Currently open trials in the same condition.

Other 5 Santé trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03368703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing